Letter to the editor regarding: Lai, Jimmy Che-To, et al "Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease"

We read with great interest the study by Lai, Yang, Lee et al, which used a large multicentre cohort to establish non-invasive test thresholds—Fibrosis-4 Index (FIB-4) ≥325 or liver stiffness measurement (LSM) ≥20 kPa (or LSM ≥15 kPa in the two-step algorithm)—to guide hepatocellular carcinoma (HCC) surveillance in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).